{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:51:18Z","timestamp":1793069478551,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"VICO Therapeutics B.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12035-025-05089-9","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T15:37:09Z","timestamp":1748705829000},"page":"12768-12790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Accurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3948","authenticated-orcid":false,"given":"Bas","family":"R\u00f6ttgering","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0702-1054","authenticated-orcid":false,"given":"Janwillem","family":"Testerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3153-0137","authenticated-orcid":false,"given":"Rudie","family":"Weij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3537-3607","authenticated-orcid":false,"given":"Chantal","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-0238","authenticated-orcid":false,"given":"Nicole","family":"Datson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"5089_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","volume":"30","author":"HT Orr","year":"2007","unstructured":"Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30:575\u2013621. https:\/\/doi.org\/10.1146\/annurev.neuro.29.051605.113042","journal-title":"Annu Rev Neurosci"},{"key":"5089_CR2","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1212\/WNL.0000000000201342","volume":"100","author":"R Torii","year":"2023","unstructured":"Torii R, Hashizume A, Yamada S et al (2023) Clinical features of female carriers and prodromal male patients with spinal and bulbar muscular atrophy. Neurology 100:e84\u2013e93. https:\/\/doi.org\/10.1212\/WNL.0000000000201342","journal-title":"Neurology"},{"key":"5089_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/gm80","volume":"1","author":"JF Gusella","year":"2009","unstructured":"Gusella JF, MacDonald ME (2009) Huntington\u2019s disease: the case for genetic modifiers. Genome Med 1:80. https:\/\/doi.org\/10.1186\/gm80","journal-title":"Genome Med"},{"key":"5089_CR4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/ana.410390412","volume":"39","author":"LG Goldfarb","year":"1996","unstructured":"Goldfarb LG, Vasconcelos O, Platonov FA et al (1996) Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann Neurol 39:500\u2013506. https:\/\/doi.org\/10.1002\/ana.410390412","journal-title":"Ann Neurol"},{"key":"5089_CR5","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1212\/NXG.0000000000000155","volume":"3","author":"KP Figueroa","year":"2017","unstructured":"Figueroa KP, Hilary C, Nieves S et al (2017) Genetic analysis of age at onset variation in spinocerebellar ataxia type 2. Neurol Genet 3:e155. https:\/\/doi.org\/10.1212\/NXG.0000000000000155","journal-title":"Neurol Genet"},{"key":"5089_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/hmg\/4.6.1001","volume":"4","author":"L Sch\u00f6ls","year":"1995","unstructured":"Sch\u00f6ls L, Vieira-Saecker AMM, Sch\u00f6ls S et al (1995) Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients. Hum Mol Genet 4:1001\u20131005. https:\/\/doi.org\/10.1093\/hmg\/4.6.1001","journal-title":"Hum Mol Genet"},{"key":"5089_CR7","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1212\/WNL.49.5.1238","volume":"49","author":"R Matsumura","year":"1997","unstructured":"Matsumura R, Futamura N, Fujimoto Y et al (1997) Spinocerebellar ataxia type 6. Neurology 49:1238\u20131243. https:\/\/doi.org\/10.1212\/WNL.49.5.1238","journal-title":"Neurology"},{"key":"5089_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/hmg\/7.2.171","volume":"7","author":"J Johansson","year":"1998","unstructured":"Johansson J, Forsgren L, Sandgren O et al (1998) Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation. Hum Mol Genet 7:171\u2013176. https:\/\/doi.org\/10.1093\/hmg\/7.2.171","journal-title":"Hum Mol Genet"},{"key":"5089_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-3-319-71779-1_10","volume":"1049","author":"Y Toyoshima","year":"2018","unstructured":"Toyoshima Y, Takahashi H (2018) Spinocerebellar ataxia type 17 (SCA17). Polyglutamine Disorders 1049:219\u2013231. https:\/\/doi.org\/10.1007\/978-3-319-71779-1_10","journal-title":"Polyglutamine Disorders"},{"key":"5089_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1212\/WNL.45.1.143","volume":"45","author":"O Komure","year":"1995","unstructured":"Komure O, Sano A, Nishino N et al (1995) DNA analysis in hereditary dentatorubral-pallidoluysian atrophy. Neurology 45:143\u2013149. https:\/\/doi.org\/10.1212\/WNL.45.1.143","journal-title":"Neurology"},{"key":"5089_CR11","doi-asserted-by":"publisher","unstructured":"Atsuta N, Watanabe H, Ito M, et al (2006) s. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patient Brain 129:1446\u20131455. https:\/\/doi.org\/10.1093\/brain\/awl096","DOI":"10.1093\/brain\/awl096"},{"key":"5089_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","volume":"14","author":"AP Lieberman","year":"2019","unstructured":"Lieberman AP, Shakkottai VG, Albin RL (2019) Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol 14:1\u201327. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-012857","journal-title":"Annu Rev Pathol"},{"key":"5089_CR13","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and incidence of Huntington\u2019s disease: an updated systematic review and meta-analysis. Mov Disord 37:2327\u20132335. https:\/\/doi.org\/10.1002\/mds.29228","journal-title":"Mov Disord"},{"key":"5089_CR14","doi-asserted-by":"publisher","unstructured":"Estevam B, Matos CA, N\u00f3brega C (2023) PolyQ database\u2014an integrated database on\u00a0polyglutamine diseases. Database 2023:baad060. https:\/\/doi.org\/10.1093\/database\/baad060","DOI":"10.1093\/database\/baad060"},{"key":"5089_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000358801","volume":"42","author":"L Ruano","year":"2014","unstructured":"Ruano L, Melo C, Silva MC, Coutinho P (2014) The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 42:174\u2013183. https:\/\/doi.org\/10.1159\/000358801","journal-title":"Neuroepidemiology"},{"key":"5089_CR16","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/mds.29446","volume":"38","author":"RAM Buijsen","year":"2023","unstructured":"Buijsen RAM, Hu M, S\u00e1ez-Gonz\u00e1lez M et al (2023) Spinocerebellar ataxia type 1 characteristics in patient-derived fibroblast and iPSC-derived neuronal cultures. Mov Disord 38:1428\u20131442. https:\/\/doi.org\/10.1002\/mds.29446","journal-title":"Mov Disord"},{"key":"5089_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","volume":"98","author":"A Reiner","year":"2011","unstructured":"Reiner A, Dragatsis I, Dietrich P et al (2011) Genetics and neuropathology of Huntington\u2019s disease. Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia 98:325\u2013372. https:\/\/doi.org\/10.1016\/B978-0-12-381328-2.00014-6","journal-title":"Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia"},{"key":"5089_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0896-6273(00)80943-5","volume":"19","author":"HL Paulson","year":"1997","unstructured":"Paulson HL, Perez MK, Trottier Y et al (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19:333\u2013344. https:\/\/doi.org\/10.1016\/S0896-6273(00)80943-5","journal-title":"Neuron"},{"key":"5089_CR19","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1093\/hmg\/11.23.2905","volume":"11","author":"W Yang","year":"2002","unstructured":"Yang W, Dunlap JR, Andrews RB, Wetzel R (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11:2905\u20132917. https:\/\/doi.org\/10.1093\/hmg\/11.23.2905","journal-title":"Hum Mol Genet"},{"key":"5089_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bpa.12427","volume":"26","author":"E Mart\u00ed","year":"2016","unstructured":"Mart\u00ed E (2016) RNA toxicity induced by expanded CAG repeats in Huntington\u2019s disease. Brain Pathol 26:779\u2013786. https:\/\/doi.org\/10.1111\/bpa.12427","journal-title":"Brain Pathol"},{"key":"5089_CR21","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1038\/cddis.2013.276","volume":"4","author":"R Nalavade","year":"2013","unstructured":"Nalavade R, Griesche N, Ryan DP et al (2013) Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Dis 4:e752\u2013e752. https:\/\/doi.org\/10.1038\/cddis.2013.276","journal-title":"Cell Death Dis"},{"key":"5089_CR22","doi-asserted-by":"publisher","first-page":"8938","DOI":"10.1093\/nar\/gkr608","volume":"39","author":"A Mykowska","year":"2011","unstructured":"Mykowska A, Sobczak K, Wojciechowska M et al (2011) CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res Suppl 39:8938\u20138951. https:\/\/doi.org\/10.1093\/nar\/gkr608","journal-title":"Nucleic Acids Res Suppl"},{"key":"5089_CR23","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/mds.28795","volume":"36","author":"G Skariah","year":"2021","unstructured":"Skariah G, Albin RL (2021) Repeat RNA toxicity drives ribosomal RNA processing defects in SCA2. Mov Disord 36:2464\u20132467. https:\/\/doi.org\/10.1002\/mds.28795","journal-title":"Mov Disord"},{"key":"5089_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.neuron.2015.10.038","volume":"88","author":"M Ba\u00f1ez-Coronel","year":"2015","unstructured":"Ba\u00f1ez-Coronel M, Ayhan F, Tarabochia AD et al (2015) RAN translation in Huntington disease. Neuron 88:667\u2013677. https:\/\/doi.org\/10.1016\/j.neuron.2015.10.038","journal-title":"Neuron"},{"key":"5089_CR25","doi-asserted-by":"publisher","first-page":"166699","DOI":"10.1016\/j.jmb.2020.10.033","volume":"432","author":"M Jazurek-Ciesiolka","year":"2020","unstructured":"Jazurek-Ciesiolka M, Ciesiolka A, Komur AA et al (2020) RAN translation of the expanded CAG repeats in the SCA3 disease context. J Mol Biol 432:166699. https:\/\/doi.org\/10.1016\/j.jmb.2020.10.033","journal-title":"J Mol Biol"},{"key":"5089_CR26","doi-asserted-by":"publisher","unstructured":"Kacher R, Lejeune FX, No\u00ebl S, et al (2021) Propensity for somatic expansion increases over the course of life in Huntington disease. eLife 10:e64674. https:\/\/doi.org\/10.7554\/eLife.64674","DOI":"10.7554\/eLife.64674"},{"key":"5089_CR27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ajhg.2024.03.015","volume":"111","author":"R Kacher","year":"2024","unstructured":"Kacher R, Lejeune F-X, David I et al (2024) CAG repeat mosaicism is gene specific in spinocerebellar ataxias. Am J Hum Genet 111:913\u2013926. https:\/\/doi.org\/10.1016\/j.ajhg.2024.03.015","journal-title":"Am J Hum Genet"},{"key":"5089_CR28","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1073\/pnas.1221891110","volume":"110","author":"K Sathasivam","year":"2013","unstructured":"Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 110:2366\u20132370. https:\/\/doi.org\/10.1073\/pnas.1221891110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5089_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s10020-024-00801-2","volume":"30","author":"F Hoschek","year":"2024","unstructured":"Hoschek F, Natan J, Wagner M et al (2024) Huntingtin HTT1a is generated in a CAG repeat-length-dependent manner in human tissues. Mol Med 30:36. https:\/\/doi.org\/10.1186\/s10020-024-00801-2","journal-title":"Mol Med"},{"key":"5089_CR30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s13311-019-00777-6","volume":"16","author":"PA Egorova","year":"2019","unstructured":"Egorova PA, Bezprozvanny IB (2019) Molecular mechanisms and therapeutics for spinocerebellar ataxia type 2. Neurotherapeutics 16:1050\u20131073. https:\/\/doi.org\/10.1007\/s13311-019-00777-6","journal-title":"Neurotherapeutics"},{"key":"5089_CR31","doi-asserted-by":"publisher","first-page":"e1001021","DOI":"10.1371\/journal.pgen.1001021","volume":"6","author":"J Crespo-Barreto","year":"2010","unstructured":"Crespo-Barreto J, Fryer JD, Shaw CA et al (2010) Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet 6:e1001021. https:\/\/doi.org\/10.1371\/journal.pgen.1001021","journal-title":"PLoS Genet"},{"key":"5089_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0166-2236(00)01721-5","volume":"24","author":"E Cattaneo","year":"2001","unstructured":"Cattaneo E, Rigamonti D, Goffredo D et al (2001) Loss of normal huntingtin function: new developments in Huntington\u2019s disease research. Neurotoxins 24:182\u2013188. https:\/\/doi.org\/10.1016\/s0166-2236(00)01721-5","journal-title":"Neurotoxins"},{"key":"5089_CR33","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.3390\/ijms25126789","volume":"25","author":"NS Moldovean-Cioroianu","year":"2024","unstructured":"Moldovean-Cioroianu NS (2024) Reviewing the structure-function paradigm in polyglutamine disorders: a synergistic perspective on theoretical and experimental approaches. Int J Mol Sci 25:6789. https:\/\/doi.org\/10.3390\/ijms25126789","journal-title":"Int J Mol Sci"},{"key":"5089_CR34","first-page":"65","volume":"5","author":"J Schulte","year":"2011","unstructured":"Schulte J, Littleton JT (2011) The biological function of the huntingtin protein and its relevance to Huntington\u2019s disease pathology. Curr Trends Neurol 5:65\u201378","journal-title":"Curr Trends Neurol"},{"key":"5089_CR35","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.3390\/ijms22084249","volume":"22","author":"R Afonso-Reis","year":"2021","unstructured":"Afonso-Reis R, Afonso IT, N\u00f3brega C (2021) Current status of gene therapy research in polyglutamine spinocerebellar ataxias. Int J Mol Sci 22:4249. https:\/\/doi.org\/10.3390\/ijms22084249","journal-title":"Int J Mol Sci"},{"key":"5089_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s44321-023-00020-y","volume":"16","author":"A Bahat","year":"2024","unstructured":"Bahat A, Itzhaki E, Weiss B et al (2024) Lowering mutant huntingtin by small molecules relieves Huntington\u2019s disease symptoms and progression. EMBO Mol Med 16:523\u2013546. https:\/\/doi.org\/10.1038\/s44321-023-00020-y","journal-title":"EMBO Mol Med"},{"key":"5089_CR37","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1093\/nar\/gku385","volume":"42","author":"A Fiszer","year":"2014","unstructured":"Fiszer A, Krzyzosiak WJ (2014) Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res Suppl 42:6787\u20136810. https:\/\/doi.org\/10.1093\/nar\/gku385","journal-title":"Nucleic Acids Res Suppl"},{"key":"5089_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/brain\/awz328","volume":"143","author":"AC Silva","year":"2020","unstructured":"Silva AC, Lobo DD, Martins IM et al (2020) Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain 143:407\u2013429. https:\/\/doi.org\/10.1093\/brain\/awz328","journal-title":"Brain"},{"key":"5089_CR39","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/hmg\/ddi147","volume":"14","author":"JMV Raamsdonk","year":"2005","unstructured":"Raamsdonk JMV, Pearson J, Rogers DA et al (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:1379\u20131392. https:\/\/doi.org\/10.1093\/hmg\/ddi147","journal-title":"Hum Mol Genet"},{"key":"5089_CR40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nature06731","volume":"452","author":"J Lim","year":"2008","unstructured":"Lim J, Crespo-Barreto J, Jafar-Nejad P et al (2008) Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452:713\u2013718. https:\/\/doi.org\/10.1038\/nature06731","journal-title":"Nature"},{"key":"5089_CR41","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/ejhg.2015.21","volume":"23","author":"L Damaj","year":"2015","unstructured":"Damaj L, Lupien-Meilleur A, Lortie A et al (2015) CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms. Eur J Hum Genet 23:1505\u20131512. https:\/\/doi.org\/10.1038\/ejhg.2015.21","journal-title":"Eur J Hum Genet"},{"key":"5089_CR42","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1111\/bcp.16202","volume":"90","author":"L Gao","year":"2024","unstructured":"Gao L, Bhattacharyya A, Beers B et al (2024) Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: a first-in-human study. Br J Clin Pharmacol 90:3242\u20133251. https:\/\/doi.org\/10.1111\/bcp.16202","journal-title":"Br J Clin Pharmacol"},{"key":"5089_CR43","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMc2300400","volume":"389","author":"P McColgan","year":"2023","unstructured":"McColgan P, Thobhani A, Boak L et al (2023) Tominersen in adults with manifest Huntington\u2019s disease. N Engl J Med Overseas Ed 389:2203\u20132205. https:\/\/doi.org\/10.1056\/NEJMc2300400","journal-title":"N Engl J Med Overseas Ed"},{"key":"5089_CR44","unstructured":"Wave Life Sciences USA, inc (2024) Wave life sciences announces positive results from phase 1b\/2a SELECT-HD trial with first clinical demonstration of allele-selective mutant huntingtin lowering in Huntington\u2019s disease. wavelifesciences. https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-positive-results-phase-1b2a-select. Accessed on 09 January 2025"},{"key":"5089_CR45","doi-asserted-by":"publisher","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","volume":"12","author":"NA Datson","year":"2017","unstructured":"Datson NA, Gonz\u00e1lez-Barriga A, Kourkouta E et al (2017) The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS ONE 12:e0171127. https:\/\/doi.org\/10.1371\/journal.pone.0171127","journal-title":"PLoS ONE"},{"key":"5089_CR46","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.omtn.2019.07.004","volume":"17","author":"E Kourkouta","year":"2019","unstructured":"Kourkouta E, Weij R, Gonz\u00e1lez-Barriga A et al (2019) Suppression of mutant protein expression in SCA3 and SCA1 mice using a CAG repeat-targeting antisense oligonucleotide. Mol Ther Nucleic Acids 17:601\u2013614. https:\/\/doi.org\/10.1016\/j.omtn.2019.07.004","journal-title":"Mol Ther Nucleic Acids"},{"key":"5089_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5214821","volume":"2019","author":"TAJ Butler","year":"2019","unstructured":"Butler TAJ, Paul JW, Chan E-C et al (2019) Misleading Westerns: common quantification mistakes in Western blot densitometry and proposed corrective measures. Biomed Res Int 2019:1\u201315. https:\/\/doi.org\/10.1155\/2019\/5214821","journal-title":"Biomed Res Int"},{"key":"5089_CR48","doi-asserted-by":"publisher","unstructured":"Janes KA (2015) An analysis of critical factors for quantitative immunoblotting. Sci Signal 8:rs2. https:\/\/doi.org\/10.1126\/scisignal.2005966","DOI":"10.1126\/scisignal.2005966"},{"key":"5089_CR49","doi-asserted-by":"publisher","first-page":"113608","DOI":"10.1016\/j.ab.2020.113608","volume":"593","author":"L Pillai-Kastoori","year":"2020","unstructured":"Pillai-Kastoori L, Schutz-Geschwender AR, Harford JA (2020) A systematic approach to quantitative Western blot analysis. Anal Biochem 593:113608. https:\/\/doi.org\/10.1016\/j.ab.2020.113608","journal-title":"Anal Biochem"},{"key":"5089_CR50","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/elps.200800720","volume":"30","author":"M Gassmann","year":"2009","unstructured":"Gassmann M, Grenacher B, Rohde B, Vogel J (2009) Quantifying Western blots: pitfalls of densitometry. Electrophoresis 30:1845\u20131855. https:\/\/doi.org\/10.1002\/elps.200800720","journal-title":"Electrophoresis"},{"key":"5089_CR51","doi-asserted-by":"publisher","first-page":"115198","DOI":"10.1016\/j.ab.2023.115198","volume":"674","author":"PA Rees","year":"2023","unstructured":"Rees PA, Lowy RJ (2023) Optimizing reduction of Western blotting analytical variations: use of replicate test samples, multiple normalization methods, and sample loading positions. Anal Biochem 674:115198. https:\/\/doi.org\/10.1016\/j.ab.2023.115198","journal-title":"Anal Biochem"},{"key":"5089_CR52","doi-asserted-by":"publisher","first-page":"v","DOI":"10.1038\/nmeth.f.353","volume":"8","author":"U Nguyen","year":"2011","unstructured":"Nguyen U, Squaglia N, Boge A, Fung PA (2011) The Simple Western\u2122: a gel-free, blot-free, hands-free Western blotting reinvention. Nat Methods 8:v\u2013vi. https:\/\/doi.org\/10.1038\/nmeth.f.353","journal-title":"Nat Methods"},{"key":"5089_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/mps6020043","volume":"6","author":"A Sormunen","year":"2023","unstructured":"Sormunen A, Koivulehto E, Alitalo K et al (2023) Comparison of automated and traditional Western blotting methods. Methods Protoc 6:43. https:\/\/doi.org\/10.3390\/mps6020043","journal-title":"Methods Protoc"},{"key":"5089_CR54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12967-015-0537-6","volume":"13","author":"J-Q Chen","year":"2015","unstructured":"Chen J-Q, Wakefield LM, Goldstein DJ (2015) Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. J Transl Med 13:182. https:\/\/doi.org\/10.1186\/s12967-015-0537-6","journal-title":"J Transl Med"},{"key":"5089_CR55","doi-asserted-by":"publisher","first-page":"8730","DOI":"10.1074\/jbc.274.13.8730","volume":"274","author":"LM Ellerby","year":"1999","unstructured":"Ellerby LM, Andrusiak RL, Wellington CL et al (1999) Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 274:8730\u20138736. https:\/\/doi.org\/10.1074\/jbc.274.13.8730","journal-title":"J Biol Chem"},{"key":"5089_CR56","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1111\/j.1742-4658.2010.07893.x","volume":"277","author":"Y Suzuki","year":"2010","unstructured":"Suzuki Y, Nakayama K, Hashimoto N, Yazawa I (2010) Proteolytic processing regulates pathological accumulation in dentatorubral-pallidoluysian atrophy. FEBS J 277:4873\u20134887. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07893.x","journal-title":"FEBS J"},{"key":"5089_CR57","doi-asserted-by":"publisher","first-page":"13047","DOI":"10.1074\/jbc.M211224200","volume":"278","author":"FC Nucifora Jr","year":"2003","unstructured":"Nucifora FC Jr, Ellerby LM, Wellington CL et al (2003) Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J Biol Chem 278:13047\u201313055. https:\/\/doi.org\/10.1074\/jbc.M211224200","journal-title":"J Biol Chem"},{"key":"5089_CR58","first-page":"378","volume":"4","author":"Y Suzuki","year":"2011","unstructured":"Suzuki Y, Yazawa I (2011) Pathological accumulation of atrophin-1 in dentatorubralpallidoluysian atrophy. Int J Clin Exp Pathol 4:378\u2013384","journal-title":"Int J Clin Exp Pathol"},{"key":"5089_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13024-015-0018-7","volume":"10","author":"MM Evers","year":"2015","unstructured":"Evers MM, Schut MH, Pepers BA et al (2015) Making (anti-) sense out of huntingtin levels in Huntington disease. Mol Neurodegener 10:21. https:\/\/doi.org\/10.1186\/s13024-015-0018-7","journal-title":"Mol Neurodegener"},{"key":"5089_CR60","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1021\/acschemneuro.8b00027","volume":"9","author":"F Matthes","year":"2018","unstructured":"Matthes F, Massari S, Bochicchio A et al (2018) Reducing mutant huntingtin protein expression in living cells by a newly identified RNA CAG binder. ACS Chem Neurosci 9:1399\u20131408. https:\/\/doi.org\/10.1021\/acschemneuro.8b00027","journal-title":"ACS Chem Neurosci"},{"key":"5089_CR61","doi-asserted-by":"publisher","first-page":"19831","DOI":"10.1074\/jbc.M001475200","volume":"275","author":"CL Wellington","year":"2000","unstructured":"Wellington CL, Singaraja R, Ellerby L et al (2000) Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 275:19831\u201319838. https:\/\/doi.org\/10.1074\/jbc.M001475200","journal-title":"J Biol Chem"},{"key":"5089_CR62","doi-asserted-by":"publisher","first-page":"9158","DOI":"10.1074\/jbc.273.15.9158","volume":"273","author":"CL Wellington","year":"1998","unstructured":"Wellington CL, Ellerby LM, Hackam AS et al (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273:9158\u20139167. https:\/\/doi.org\/10.1074\/jbc.273.15.9158","journal-title":"J Biol Chem"},{"key":"5089_CR63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/humu.9055","volume":"20","author":"S He\u0107imovi\u0107","year":"2002","unstructured":"He\u0107imovi\u0107 S, Klepac N, Vlasi\u0107 J et al (2002) Genetic background of Huntington disease in Croatia: molecular analysis of CAG, CCG, and Delta2642 (E2642del) polymorphisms. Hum Mutat 20:233\u2013233. https:\/\/doi.org\/10.1002\/humu.9055","journal-title":"Hum Mutat"},{"key":"5089_CR64","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS et al (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B:397\u2013408. https:\/\/doi.org\/10.1002\/ajmg.b.30992","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"5089_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0022-1759(02)00523-9","volume":"274","author":"BT Kurien","year":"2003","unstructured":"Kurien BT, Scofield RH (2003) Protein blotting: a review. J Immunol Methods 274:1\u201315. https:\/\/doi.org\/10.1016\/s0022-1759(02)00523-9","journal-title":"J Immunol Methods"},{"key":"5089_CR66","unstructured":"ProteinSimple (2014) Simple Western size assay development guide. Bio-Techne resources. https:\/\/resources.bio-techne.com\/bio-techne-assets\/docs\/literature\/042-889_Rev1_Size_Assay_Development_Guide.pdf. Accessed 09 January 2025"},{"key":"5089_CR67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/02648725.2013.801232","volume":"29","author":"G Xu","year":"2013","unstructured":"Xu G, Jaffrey SR (2013) Proteomic identification of protein ubiquitination events. Biotechnol Genet Eng Rev 29:73\u2013109. https:\/\/doi.org\/10.1080\/02648725.2013.801232","journal-title":"Biotechnol Genet Eng Rev"},{"key":"5089_CR68","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41598-021-81986-y","volume":"11","author":"N Bagwan","year":"2021","unstructured":"Bagwan N, Ali HHE, Lundby A (2021) Proteome-wide profiling and mapping of post translational modifications in human hearts. Sci Rep 11:2184. https:\/\/doi.org\/10.1038\/s41598-021-81986-y","journal-title":"Sci Rep"},{"key":"5089_CR69","doi-asserted-by":"publisher","unstructured":"Alegre-Mart\u00ed A, Jim\u00e9nez-Panizo A, Mart\u00ednez-T\u00e9bar A, et al (2023) A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance. Sci Adv 9:eade2175. https:\/\/doi.org\/10.1126\/sciadv.ade2175","DOI":"10.1126\/sciadv.ade2175"},{"key":"5089_CR70","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fncel.2018.00290","volume":"12","author":"L Wan","year":"2018","unstructured":"Wan L, Xu K, Chen Z et al (2018) Roles of post-translational modifications in spinocerebellar ataxias. Front Cell Neurosci 12:290. https:\/\/doi.org\/10.3389\/fncel.2018.00290","journal-title":"Front Cell Neurosci"},{"key":"5089_CR71","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41419-024-06812-5","volume":"15","author":"RG Costa","year":"2024","unstructured":"Costa RG, Concei\u00e7\u00e3o A, Matos CA, N\u00f3brega C (2024) The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease. Cell Death Dis 15:415. https:\/\/doi.org\/10.1038\/s41419-024-06812-5","journal-title":"Cell Death Dis"},{"key":"5089_CR72","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1073858410390378","volume":"17","author":"DE Ehrnhoefer","year":"2011","unstructured":"Ehrnhoefer DE, Sutton L, Hayden MR (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17:475\u2013492. https:\/\/doi.org\/10.1177\/1073858410390378","journal-title":"Neuroscientist"},{"key":"5089_CR73","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1073\/pnas.0813167106","volume":"106","author":"A Rath","year":"2009","unstructured":"Rath A, Glibowicka M, Nadeau VG et al (2009) Detergent binding explains anomalous SDS-PAGE migration of membrane proteins. Proc Natl Acad Sci U S A 106:1760\u20131765. https:\/\/doi.org\/10.1073\/pnas.0813167106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5089_CR74","doi-asserted-by":"publisher","first-page":"10745","DOI":"10.1074\/jbc.m709211200","volume":"283","author":"A Shirai","year":"2008","unstructured":"Shirai A, Matsuyama A, Yashiroda Y et al (2008) Global analysis of gel mobility of proteins and its use in target identification. J Biol Chem 283:10745\u201310752. https:\/\/doi.org\/10.1074\/jbc.m709211200","journal-title":"J Biol Chem"},{"key":"5089_CR75","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/elps.202000199","volume":"42","author":"R Wiesner","year":"2021","unstructured":"Wiesner R, Scheller C, Krebs F et al (2021) A comparative study of CE-SDS, SDS-PAGE, and Simple Western: Influences of sample preparation on molecular weight determination of proteins. Electrophoresis 42:206\u2013218. https:\/\/doi.org\/10.1002\/elps.202000199","journal-title":"Electrophoresis"},{"key":"5089_CR76","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.3390\/molecules23102564","volume":"23","author":"T Wang","year":"2018","unstructured":"Wang T, Larcher LM, Ma L, Veedu RN (2018) Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides. Molecules 23:2564. https:\/\/doi.org\/10.3390\/molecules23102564","journal-title":"Molecules"},{"key":"5089_CR77","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bbagrm.2013.01.011","volume":"1829","author":"X-H Liang","year":"2013","unstructured":"Liang X-H, Hart CE, Crooke ST (2013) Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. Biochim Biophys Acta Gene Regul Mech 1829:455\u2013468. https:\/\/doi.org\/10.1016\/j.bbagrm.2013.01.011","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"5089_CR78","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1038\/s41467-019-12282-7","volume":"10","author":"M Iida","year":"2019","unstructured":"Iida M, Sahashi K, Kondo N et al (2019) Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nat Commun 10:4262. https:\/\/doi.org\/10.1038\/s41467-019-12282-7","journal-title":"Nat Commun"},{"key":"5089_CR79","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/518027a","volume":"518","author":"A Bradbury","year":"2015","unstructured":"Bradbury A, Pl\u00fcckthun A (2015) Reproducibility: standardize antibodies used in research. Nature 518:27\u201329. https:\/\/doi.org\/10.1038\/518027a","journal-title":"Nature"},{"key":"5089_CR80","doi-asserted-by":"publisher","unstructured":"Bradbury ARM, Trinklein ND, Thie H, et al (2018) When monoclonal antibodies are not monospecific: hybridomas frequently express additional functional variable regions. mAbs 10:539\u2013546. https:\/\/doi.org\/10.1080\/19420862.2018.1445456","DOI":"10.1080\/19420862.2018.1445456"},{"key":"5089_CR81","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/jci80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest 125:1979\u20131986. https:\/\/doi.org\/10.1172\/jci80743","journal-title":"J Clin Invest"},{"key":"5089_CR82","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/mds.28749","volume":"36","author":"J H\u00fcbener-Schmid","year":"2021","unstructured":"H\u00fcbener-Schmid J, Kuhlbrodt K, Peladan J et al (2021) Polyglutamine-expanded ataxin-3: a target engagement marker for spinocerebellar ataxia type 3 in peripheral blood. Mov Disord 36:2675\u20132681. https:\/\/doi.org\/10.1002\/mds.28749","journal-title":"Mov Disord"},{"key":"5089_CR83","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00415-020-10274-y","volume":"268","author":"K Gonsior","year":"2021","unstructured":"Gonsior K, Kaucher GA, Pelz P et al (2021) PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study. J Neurol 268:1304\u20131315. https:\/\/doi.org\/10.1007\/s00415-020-10274-y","journal-title":"J Neurol"},{"key":"5089_CR84","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.2440","volume":"216","author":"F Pont\u00e9n","year":"2008","unstructured":"Pont\u00e9n F, Jirstr\u00f6m K, Uhlen M (2008) The Human Protein Atlas\u2014a tool for pathology. J Pathol 216:387\u2013393. https:\/\/doi.org\/10.1002\/path.2440","journal-title":"J Pathol"},{"key":"5089_CR85","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42466-019-0025-1","volume":"1","author":"I Lastres-Becker","year":"2019","unstructured":"Lastres-Becker I, Nonis D, Nowock J, Auburger G (2019) New alternative splicing variants of the ATXN2 transcript. Neurol Res Pract 1:22. https:\/\/doi.org\/10.1186\/s42466-019-0025-1","journal-title":"Neurol Res Pract"},{"key":"5089_CR86","doi-asserted-by":"publisher","unstructured":"Lim WF, Forouhan M, Roberts TC, et al (2021) Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity. Sci Adv 7:eabi6896. https:\/\/doi.org\/10.1126\/sciadv.abi6896","DOI":"10.1126\/sciadv.abi6896"},{"key":"5089_CR87","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1074\/jbc.ra118.005801","volume":"294","author":"D Weish\u00e4upl","year":"2019","unstructured":"Weish\u00e4upl D, Schneider J, Pinheiro BP et al (2019) Physiological and pathophysiological characteristics of ataxin-3 isoforms. J Biol Chem 294:644\u2013661. https:\/\/doi.org\/10.1074\/jbc.ra118.005801","journal-title":"J Biol Chem"},{"key":"5089_CR88","doi-asserted-by":"publisher","first-page":"106456","DOI":"10.1016\/j.nbd.2024.106456","volume":"193","author":"M Raposo","year":"2024","unstructured":"Raposo M, H\u00fcbener-Schmid J, Tagett R et al (2024) Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3\/Machado-Joseph disease. Neurobiol Dis 193:106456. https:\/\/doi.org\/10.1016\/j.nbd.2024.106456","journal-title":"Neurobiol Dis"},{"key":"5089_CR89","doi-asserted-by":"publisher","first-page":"57082","DOI":"10.3791\/57082","volume":"132","author":"J Ochaba","year":"2018","unstructured":"Ochaba J, Morozko EL, O\u2019Rourke JG, Thompson LM (2018) Fractionation for resolution of soluble and insoluble huntingtin species. J Vis Exp 132:57082. https:\/\/doi.org\/10.3791\/57082","journal-title":"J Vis Exp"},{"key":"5089_CR90","doi-asserted-by":"publisher","first-page":"e44785","DOI":"10.1371\/journal.pone.0044785","volume":"7","author":"A Cohen","year":"2012","unstructured":"Cohen A, Ross L, Nachman I, Bar-Nun S (2012) Aggregation of PolyQ proteins is increased upon yeast aging and affected by Sir2 and Hsf1: novel quantitative biochemical and microscopic assays. PLoS ONE 7:e44785. https:\/\/doi.org\/10.1371\/journal.pone.0044785","journal-title":"PLoS ONE"},{"key":"5089_CR91","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506. https:\/\/doi.org\/10.1016\/S0092-8674(00)81369-0","journal-title":"Cell"},{"key":"5089_CR92","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/ilar.48.4.356","volume":"48","author":"S Ramaswamy","year":"2007","unstructured":"Ramaswamy S, McBride JL, Kordower JH (2007) Animal models of Huntington\u2019s disease. ILAR J 48:356\u2013373. https:\/\/doi.org\/10.1093\/ilar.48.4.356","journal-title":"ILAR J"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05089-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T18:02:17Z","timestamp":1757786537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05089-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5089"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05089-9","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Financial interest: All authors are employed and paid by VICO Therapeutics B.V. and hold employee stock options.\u00a0","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}